Investors

Copyright West LLC. Minimum 15 minutes delayed.

News Release

<< Back
May 15, 2015

OvaScience’s AUGMENT Fertility Treatment Continues to Demonstrate Improved Pregnancy Rates in Women with Very Poor Prognoses

CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 15, 2015-- OvaScienceSM (NASDAQ: OVAS), a global fertility company focused on the discovery, development and commercialization of new treatment options, announced today additional clinical experience with the Company’s AUGMENTSM fertility treatment, showing improved clinical pregnancy rates in women with poor prognoses, including poor egg health and embryo quality, who previously failed multiple cycles of in vitro fertilization (IVF). Robert F. Casper, M.D., F.R.C.S.(C), Medical Director of TCART Fertility Partners of Toronto, Ontario, summarized his clinical experience with the AUGMENT treatment during an oral presentation at the 21st COGI (Controversies in Obstetrics, Gynecology & Infertility) Congress: Innovation in Reproductive Medicine in Frankfurt, Germany. The AUGMENT treatment is not available in the United States.

“The increased pregnancy rates with the AUGMENT treatment, which showed at least a three-fold increase over these women’s prior histories, are promising, particularly because they have historically had poor prognoses with multiple failed IVF cycles and other fertility risk factors. It was unlikely that another IVF cycle would have produced a different outcome, which is why we recommended the AUGMENT treatment,” said Dr. Casper.

Dr. Casper reported outcomes in 34 women with poor egg health and embryo quality who had a 10-11 percent clinical pregnancy rate on average, and only a one percent live birth rate on average, based on all previous IVF cycles combined. The women, whose ages range from 26-44 (average age=36), had failed one-to-five previous IVF cycles, and with only one AUGMENT treatment cycle, showed a three-to-four-fold increase in clinical pregnancy rates, with nine ongoing clinical pregnancies including a healthy live birth. In addition, nine of the women have frozen AUGMENT embryos, including some women who failed to get pregnant with one embryo transfer, which could be used in future embryo transfers.

        All Previous IVF History       AUGMENT Treatment
Total cycles initiated       71       34
Average cycles initiated per patient       2       1
Total embryo transfers (fresh & frozen)       79       26

Clinical pregnancies1

      8       12
Clinical pregnancy rate per cycle initiated
(4 of the 34 women did not receive AUGMENT treatment)
      11%       35%

Clinical pregnancy rate per embryo transfer2

      10%       46%
Ongoing clinical pregnancies and live births

(rate per cycle initiated)

      No ongoing with 1 live birth (1%)       9 including 1 live birth (26%)

1A clinical pregnancy is confirmed by ultrasound and the presence of a gestational sac in the uterus, which occurs at approximately 5-10 weeks.
2An embryo transfer is the placement of one or more embryos into the uterus. An IVF cycle can consist of multiple embryo transfers with both fresh and frozen transfers.

The results reported in the presentation represent experiences from a small number of patients with different diagnoses, ages and prior IVF history.

“We are pleased that physicians continue to share their ongoing clinical experiences with the AUGMENT treatment,” said Michelle Dipp, M.D., Ph.D., Chief Executive Officer of OvaScience. “This presentation shows continued improved pregnancy rates compared to these women’s prior histories, which is consistent with the outcomes seen across all the clinics currently offering the AUGMENT treatment. We look forward to more clinical pregnancies and healthy births as women continue to use the AUGMENT treatment.”

AUGMENT treatment information from Dr. Casper’s oral presentation is available on www.ovascience.com/technology/publications.

About the AUGMENTSM Treatment

The AUGMENT treatment is the first fertility treatment available to patients based on OvaScience’s proprietary egg precursor (EggPCSM) cell technology. The AUGMENT treatment is designed to improve the health of a woman’s existing eggs, and enhance the IVF procedure. The AUGMENT treatment uses energy-producing mitochondria from a woman’s own EggPC cells, which are immature egg cells found in the protective lining of the ovaries, to supplement the existing mitochondria in her eggs. This treatment is designed to improve egg health by increasing the eggs’ energy levels for embryo development. Egg health is a key factor in IVF success. The AUGMENT treatment is available in select international IVF clinics, and initial positive clinical experiences of pregnancies with the treatment have been reported. The AUGMENT treatment is not available in the United States.

For more information, please visit www.augmenttreatment.com.

About OvaScience

OvaScience (NASDAQ: OVAS) is a global fertility company dedicated to improving treatment options for women around the world. OvaScience is discovering, developing and commercializing new fertility treatments because we believe women deserve more options. Each OvaScience treatment is based on the Company’s proprietary technology platform that leverages the breakthrough discovery of egg precursor (EggPCSM) cells – immature egg cells found inside the protective ovarian lining. The AUGMENTSM treatment, a fertility option specifically designed to improve egg health, is available in certain IVF clinics in select international regions outside of the United States. OvaScience is developing the OvaPrimeSM treatment, which could increase a woman’s egg reserve, and the OvaTureSM treatment, a potential next-generation IVF treatment that could help a woman produce healthy, young, fertilizable eggs without hormone injections. For more information, please visit www.ovascience.com and connect with us on Twitter and Facebook.

Forward-Looking Statements

This press release includes forward-looking statements about the Company’s plans for the AUGMENT treatment and two fertility treatments in development, as well as statements about future use of frozen embryos. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including risks related to: the possibility that international IVF clinics that we work with may determine not to begin or continue providing the AUGMENT treatment for commercial or other reasons; our expectation that the AUGMENT treatment and OvaPrime treatment meet the requirements of a class of products exempt from premarket review and approval under applicable regulations in those countries where we have launched or plan to introduce the AUGMENT treatment and plan to introduce the OvaPrime treatment; the commercial ramp up of the AUGMENT treatment, which we expect will depend upon the successful transition of ACE clinics to commercial operations, the addition of new ACE clinics, and the results from ACE clinic experience as they become available; the science underlying our treatment and treatments in development (including the AUGMENT, OvaPrime and OvaTure treatments), which is unproven; our ability to obtain regulatory approval where necessary for our potential treatments; our ability to develop our potential treatments, including the OvaPrime and OvaTure treatments, on the timelines we expect, if at all; our ability to commercialize the AUGMENT treatment and our potential treatments, including the OvaPrime treatment, on the timelines we expect, if at all; as well as those risks more fully discussed in the “Risk Factors” section of our most recently filed Quarterly Report on Form 10-Q and/or Annual Report on Form 10-K. The forward-looking statements contained in this press release reflect our current views with respect to future events. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements in the future, we specifically disclaim any obligation to do so. These forward-looking statements should not be relied upon as representing our view as of any date subsequent to the date hereof.

###

Source: OvaScience

OvaScience
Investors
Theresa McNeely, 617-299-7356
EVP, Chief Communications Officer
tmcneely@ovascience.com
or
Media
Cara Mayfield, 617-714-9638
Director, Corporate Communications
cmayfield@ovascience.com